|
Age, mean years (SD)
|
62.0 (8.5)
|
61.6 (8.6)
|
|
Sex, male (%)
|
151 (59)
|
133 (56)
|
|
BMI, median kg/m2 (IQR)
|
28.4 (25.3, 32.5)
|
28.6 (25.5, 32.6)
|
|
Ethnicity, n (%)
|
|
African
|
34 (13)
|
33 (14)
|
|
South Asian
|
142 (56)
|
127 (54)
|
|
Caucasian
|
79 (31)
|
75 (32)
|
|
Duration of diabetes, median years (IQR)
|
13 (8, 19)
|
13 (8, 19)
|
|
Microvascular disease, n (%)
|
123 (48)
|
114 (48)
|
|
Retinopathy, n (%)
|
99 (38)
|
90 (38)
|
|
Hyperlipidaemia, n (%)
|
203 (78)
|
187 (79)
|
|
Hypertension, n (%)
|
192 (74)
|
176 (74)
|
|
Smoking, n (%)
|
20 (8)
|
19 (8)
|
|
Statin use, n (%)
|
188 (73)
|
173 (73)
|
|
Family history of premature ischaemic heart disease, n (%)
|
51 (20)
|
45 (19)
|
|
SBP, mm Hg (SD)
|
137.3 (15.8)
|
137.1 (15.7)
|
|
HbA1c, median mmol/mol (IQR)
|
63.0 (51.9, 77.0)
|
64.0 (51.9, 77.0)
|
|
eGFR, mean mL/min/1.73 m2 (SD)
|
80.9 ± 18.4
|
80.9 ± 18.8
|
|
CAC (AU), median (IQR)
|
109 (1, 322)
|
82 (0, 266)
|
|
Total cholesterol, mean mmol/L (SD)
|
4.05 (0.92)
|
4.08 (0.93)
|
|
LDL-C, mean mmol/L (SD)
|
2.10 (0.88)
|
2.12 (0.89)
|
|
HDL-C, mean mmol/L (SD)
|
1.29 (0.39)
|
1.29 (0.39)
|
|
Triglycerides, median mmol/L (IQR)
|
1.4 (0.9, 1.9)
|
1.4 (1.0, 1.9)
|
|
Total cholesterol:HDL-C ratio, mean (SD)
|
3.41 (1.2)
|
2.41 (1.2)
|
|
Medications for diabetes, n (%)
| | |
|
Metformin
|
232 (90)
|
214 (90)
|
|
Sulphonylureas
|
87 (34)
|
78 (33)
|
|
Thiazolidinediones
|
21 (8)
|
18 (8)
|
|
GLP-1 agonists
|
36 (14)
|
34 (14)
|
|
DPP-4 Inhibitors
|
50 (19)
|
47 (20)
|
|
Insulin
|
139 (54)
|
132 (55)
|
|
ACEi/ARB
|
163 (63)
|
149 (62)
|
